BACKGROUND: The impact of computed tomography (CT)-based follow-up for the detection of resectable disease recurrence following surgery for colorectal liver metastases (CRLM) was evaluated. METHODS: Some 705 patients undergoing resection of CRLM between January 1993 and March 2007 were included. Surveillance comprised 3-monthly CT (thorax, abdomen and pelvis) in the first 2 years after surgery, 6 monthly for 3 years and annually from years 6 to 10. Survival differences following recurrence between patients managed surgically and palliatively were determined, and the cost was calculated. RESULTS: Five-year disease-free and overall survival rates were 28.3 and 32.3 per cent respectively. Of 402 patients who developed recurrence within 2 years, 88 were treated with liver resection alone and 36 with lung and/or liver resection. Their 5-year overall survival rates were 31 and 30 per cent respectively, compared with 3.9 per cent in 278 patients managed palliatively (P < 0.001). For each 3-month interval during the first year of follow-up, patients with recurrence treated surgically had better overall survival than those treated palliatively. The cost of surveillance that identified 124 patients amenable to further resection was 12,338 pounds per operated recurrence. Assuming that patients with recurrence gained 5 years' survival, the mean survival gain was 4.28 years per resection and the cost per life-year gained was 2883 pounds. CONCLUSION: Intensive 3-monthly CT surveillance after liver resection for CRLM detects recurrence that is amenable to further resection in a considerable number of patients. These patients have significantly better survival with a reasonable cost per life-year gained.
BACKGROUND: The impact of computed tomography (CT)-based follow-up for the detection of resectable disease recurrence following surgery for colorectal liver metastases (CRLM) was evaluated. METHODS: Some 705 patients undergoing resection of CRLM between January 1993 and March 2007 were included. Surveillance comprised 3-monthly CT (thorax, abdomen and pelvis) in the first 2 years after surgery, 6 monthly for 3 years and annually from years 6 to 10. Survival differences following recurrence between patients managed surgically and palliatively were determined, and the cost was calculated. RESULTS: Five-year disease-free and overall survival rates were 28.3 and 32.3 per cent respectively. Of 402 patients who developed recurrence within 2 years, 88 were treated with liver resection alone and 36 with lung and/or liver resection. Their 5-year overall survival rates were 31 and 30 per cent respectively, compared with 3.9 per cent in 278 patients managed palliatively (P < 0.001). For each 3-month interval during the first year of follow-up, patients with recurrence treated surgically had better overall survival than those treated palliatively. The cost of surveillance that identified 124 patients amenable to further resection was 12,338 pounds per operated recurrence. Assuming that patients with recurrence gained 5 years' survival, the mean survival gain was 4.28 years per resection and the cost per life-year gained was 2883 pounds. CONCLUSION: Intensive 3-monthly CT surveillance after liver resection for CRLM detects recurrence that is amenable to further resection in a considerable number of patients. These patients have significantly better survival with a reasonable cost per life-year gained.
Authors: Arthur J Richardson; Tony C Y Pang; Emma Johnston; Michael J Hollands; Vincent W T Lam; Henry C C Pleass Journal: J Gastrointest Surg Date: 2013-09-04 Impact factor: 3.452
Authors: Dhanwant Gomez; Abed M Zaitoun; Antonella De Rosa; Sina Hossaini; Ian J Beckingham; Adam Brooks; Iain C Cameron Journal: HPB (Oxford) Date: 2014-03-12 Impact factor: 3.647
Authors: Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers Journal: Nat Rev Clin Oncol Date: 2016-12-20 Impact factor: 66.675
Authors: Dhanwant Gomez; Dariush Kamali; W Keith Dunn; Ian J Beckingham; Adam Brooks; Iain C Cameron Journal: HPB (Oxford) Date: 2012-05-14 Impact factor: 3.647
Authors: Fabio Ausania; Theodoris Tsirlis; Steven A White; Jeremy J French; Bryon C Jaques; Richard M Charnley; Derek M Manas Journal: HPB (Oxford) Date: 2013-01-07 Impact factor: 3.647
Authors: Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó Journal: Pathol Oncol Res Date: 2013-07-19 Impact factor: 3.201
Authors: Boris Galjart; Eric P van der Stok; Joost Rothbarth; Dirk J Grünhagen; Cornelis Verhoef Journal: Ann Surg Oncol Date: 2016-07-08 Impact factor: 5.344
Authors: Karin Nielsen; Hester J Scheffer; Indra C Pieters; Aukje A J M van Tilborg; Jan-Hein T M van Waesberghe; Daniela E Oprea-Lager; Martijn R Meijerink; Geert Kazemier; Otto S Hoekstra; Hermien W H Schreurs; Colin Sietses; Sybren Meijer; Emile F I Comans; Petrousjka M P van den Tol Journal: BMC Med Imaging Date: 2014-08-08 Impact factor: 1.930